RE:RE:RE:RE:RE:Just thought I would pass this along Let's assume they need another financing if they're funding a NASH Ph3, and that will likely be bigger. If this financing and the next year helps the SP get to a good place and they do that 2nd financing then maybe we have to see the overall strategy as an average of the two financings. Just tryin' to shine the turd!
jfm1330 wrote: I am tired of reading about anger, frustration or indignation about the last financing. What's the point of repeating it over and over? Hey! We know it! If someone thinks the BOD and management are crooks and/or a bunch of incompetents, just sell the stock and move on.
If Thera is going to finally be a success story, this financing will only be one event in a serie of events, some totally in favor of the company, and other less so, like this financing. If oncology ends up as a blockbuster, imagine how good a deal for shareholders it will have been, same for NASH. The company got both for almost nothing. They got Trogarzo's rights for almost nothing upfront.
Also, the worst thing for somebody taking an insurance policy, is to say it was a bad move at the end of it because you did not need to use it.